Case Challenges in the Use of New Pharmacoenhanced Protease Inhibitors
Infectious Diseases
Curriculum:
New Opportunities for the Patient with HIV Infection
New Opportunities for the Patient with HIV Infection
Credits:
0.5 ACPE 0.5 AMA PRA Category 1 Credit(s) ™
0.5 ACPE 0.5 AMA PRA Category 1 Credit(s) ™
Launch Date:
December 01, 2015
December 01, 2015
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Infectious disease specialists; primary care physicians; nurse practitioners, physician assistants; and allied health care providers
Relevant Terms:
HIV; drug-drug interactions; adherence; adverse drug events
Adriana Andrade, MD, MPH, FACP
Adriana Andrade, MD, MPH, FACP
Associate Professor of Medicine
Johns Hopkins Medicine
Baltimore, MD
Bio
Dr. Adriana Andrade is an Associate Professor of Medicine at the Johns Hopkins University. She received her MD degree from the University Federal de Minas Gerais, Belo Horizonte, Brazil. Dr. Andrade is formally trained in public health and holds a M.P.H. degree from the Johns Hopkins University School of Hygiene and Public Health. She is also board certified in internal medicine and completed a fellowship in clinical pharmacology at the Johns Hopkins University. Dr. Andrade is a Co-Principal Investigator at the Johns Hopkins AIDS Clinical Trials Unit. Dr. Andrade has worked internationally providing training and giving lectures on drug-drug interactions with antiretroviral agents in Brazil, South Africa and India. She also participated in the development of clinical materials used to standardize delivery of care in local HIV clinics in Pretoria, South Africa. She is involved in the development of educational materials used in resource poorsettings for the management and treatment of HIV/AIDS and its complications. Her main areas of research interest involve adherence to antiretroviral therapy and drug interactions involving antiretrovirals and complementary and alternative medicine agents. Dr. Andrade is also a clinician at the Moore HIV Clinic, at the Johns Hopkins University.
Geetanjali Chander, MD, MPH
Geetanjali Chander, MD, MPH
Director, General Internal Medicine Fellowship Program
Associate Professor of Medicine
Johns Hopkins Medicine
Baltimore, MD
Bio
Dr. Chander is an Associate Professor in the Department of Medicine, Johns Hopkins University. Her areas of expertise include pharmacologic and behavioral interventions for hazardous drinking and alcohol use disorders among HIV infected individuals. Of particular interest, her work has focused on the expansion of alcohol interventions into HIV primary care settings. She also has been PI on an NIH-funded study to reduce alcohol use among HIV infected and at risk women, a co-investigator on a randomized trial testing ondansetron for alcohol reduction among HIV infected individuals and a co-investigator on a multisite study examining the integration and implementation of alcohol pharmacotherapy into HIV care settings She has been involved in HIV and alcohol related research for since 2004. She was the recipient of a NIAAA career development award to examine the impact of psychiatric comorbidities on alcohol intervention effectiveness among HIV-infected patients. She is also an attending clinician in the Johns Hopkins HIV Clinic.
| 1. | Identify recently introduced cobicistat-boosted protease inhibitors atazanavir/cobicistat and darunavir/cobicistat and explain their unique role in treating patients with HIV. | 2. | Evaluate how the virologic efficacy and tolerability of atazanavir/cobicistat and darunavir/cobicistat will affect patient selection in clinical practice. |
| 3. | Define patient characteristics that will most benefit from the virologic efficacy, tolerability, and one-a-day dosing of cobicistat-boosted PIs. |
| 1. | Identify recently introduced cobicistat-boosted protease inhibitors atazanavir/cobicistat and darunavir/cobicistat and explain their unique role in treating patients with HIV. |
| 2. | Evaluate how the virologic efficacy and tolerability of atazanavir/cobicistat and darunavir/cobicistat will affect patient selection in clinical practice. |
| 3. | Define patient characteristics that will most benefit from the virologic efficacy, tolerability, and one-a-day dosing of cobicistat-boosted PIs. |
Jointly provided by Postgraduate Institute for Medicine and DKBMed
Release Date: December 1, 2015
Expiration Date: November 30, 2017
Physician Continuing Medical Education
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and DKBMed. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacist Continuing Education
Accreditation Statement
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.Credit Designation
Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - 0809-9999-15-298-H02-P)
Estimated time to complete this activity 30 minutes. It is estimated to take 90 minutes of the participant's time to complete the entire series (3 activities).
Type of Activity
Knowledge
Target Audience
The target audience includes 1,500 clinicians who treat HIV: infectious disease (ID) specialists, primary care physicians (PCPs), nurse practitioners (NPs), physician assistants (PAs), and allied health care providers in the RealCME network.
Educational Support
This educational activity is supported by an independent educational grant from Bristol-Myers Squibb.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Faculty
The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
Dr. Adrianna Andrade, has recieved research funding from ViiV.
Dr. Geetanjali Chander, has no real or apparent conflict to report.
Dr. Adrianna Andrade, has recieved research funding from ViiV.
Dr. Geetanjali Chander, has no real or apparent conflict to report.
Planners
The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The following DKB planners and managers, Dean Beals, Stan Pogroszewski, and Sharine Griggs, hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interest related to the content of the activity of any amount during the past 12 months.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Media
Internet
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Method of Participation and Request for Credit
Please review the program in its entirety and successfully complete the posttest with at least 70% to receive a certificate of credit.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Method of Participation and Request for Credit
Please review the program in its entirety and successfully complete the posttest with at least 70% to receive a certificate of credit.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6+ for Mac OSX 10.7 and above For video playback, install the latest version of Flash or Quicktime. | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above |
